Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene.
Gene transfer of the Escherichia coli purine nucleoside phosphorylase (PNP) results in potent cytotoxicity after administration of the prodrug fludarabine phosphate (F-araAMP). Here, we have tested whether application of this strategy in the context of replication-competent retrovirus (RCR) vectors, which can achieve highly efficient tumor-restricted transduction as well as persistent expression of transgenes, would result in effective tumor inhibition, or, alternatively, would adversely affect viral replication. We found that RCR vectors could achieve high levels of PNP expression concomitant with the efficiency of their replicative spread, with significant cell killing activity in vitro and potent therapeutic effects in vivo. In U-87 xenograft models, replicative spread of the vector resulted in progressive transmission of the PNP transgene, as evidenced by increasing PNP enzyme activity with time after vector inoculation. On F-araAMP administration, high efficiency gene transfer of PNP by the RCR vector resulted in significant suppression of tumor growth and extended survival time. As the RCR mediates stable integration of the PNP gene and continuous expression, an additional round of F-araAMP administration resulted in further survival benefit. RCR-mediated PNP suicide gene therapy thus represents a highly efficient form of intracellular chemotherapy, and may achieve effective antitumor activity with less systemic toxicity.
Tai
C-K
CK
Department of Life Science, National Chung Cheng University, Min-Hsiung, Chia-Yi, Taiwan.
Wang
W
W
Lai
Y-H
YH
Logg
C R
CR
Parker
W B
WB
Li
Y-F
YF
Hong
J S
JS
Sorscher
E J
EJ
Chen
T C
TC
Kasahara
N
N
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D004926:Escherichia coli / Q000201:enzymology*; D015316:Genetic Therapy; D005822:Genetic Vectors; D005910:Glioma / Q000235:genetics / Q000628:therapy* / Q000821:virology; D049452:Green Fluorescent Proteins / Q000378:metabolism; D006801:Humans; D015552:Injections, Intralesional; D007279:Injections, Subcutaneous; D051379:Mice; D008819:Mice, Nude; D011355:Prodrugs / Q000494:pharmacology*; D011683:Purine-Nucleoside Phosphorylase / Q000235:genetics*; D012190:Retroviridae / Q000235:genetics*; D001084:Vidarabine Phosphate / Q000031:analogs & derivatives* / Q000494:pharmacology
D000964:Antimetabolites, Antineoplastic; D011355:Prodrugs; C485184:enhanced green fluorescent protein; D001084:Vidarabine Phosphate; D049452:Green Fluorescent Proteins; C042382:fludarabine phosphate; D011683:Purine-Nucleoside Phosphorylase
Cancer Res. 2004 Sep 15;64(18):6610-5
15374975
Mol Cell Biol. 1987 Jan;7(1):379-87
3031469
Hepatology. 2000 Mar;31(3):606-14
10706550
Cancer Gene Ther. 1997 Mar-Apr;4(2):118-28
9080121
J Pharmacol Exp Ther. 2003 Mar;304(3):1280-4
12604707
J Gene Med. 2004 Jan;6(1):43-54
14716676
Hum Gene Ther. 1990 Spring;1(1):15-30
1964393
Hum Gene Ther. 2001 May 20;12(8):921-32
11387057
Clin Cancer Res. 2006 Dec 1;12(23):7108-16
17145835
Hum Gene Ther. 2000 Nov 20;11(17):2389-401
11096443
Hum Gene Ther. 2003 Jan 20;14(2):117-27
12614563
Mol Ther. 2005 Nov;12(5):842-51
16257382
Hum Gene Ther. 1991 Fall;2(3):215-9
1661171
Science. 2003 Oct 17;302(5644):415-9
14564000
Hum Gene Ther. 1997 Sep 20;8(14):1637-44
9322865
Gene Ther. 2002 Jun;9(12):759-68
12040457
Biochem Pharmacol. 1998 May 15;55(10):1673-81
9634004
Neurosurg Focus. 2006 Apr 15;20(4):E25
16709031
Gene Ther. 2004 Nov;11(21):1559-67
15343359
Acta Pathol Microbiol Scand. 1968;74(4):465-86
4313504
Cancer Gene Ther. 2007 Mar;14(3):279-86
17218950
Cancer Gene Ther. 2002 Dec;9(12):1022-35
12522441
Cancer Res. 2007 Jun 1;67(11):5345-53
17545615
Gene Ther. 2000 Oct;7(20):1738-43
11083495
J Virol. 1990 Dec;64(12):6176-83
1700832
Science. 2002 Oct 4;298(5591):34-5
12364755
J Exp Med. 1992 Oct 1;176(4):1125-35
1383375
J Gene Med. 2004 Dec;6(12):1343-57
15493036
Hum Gene Ther. 1999 Mar 1;10(4):649-57
10094208
J Virol. 2002 Dec;76(24):12783-91
12438603
Nat Med. 2001 Jul;7(7):781-7
11433341
Science. 2002 Apr 19;296(5567):497
11964471
Gene Ther. 1994 Jul;1(4):233-8
7584086
Cancer Gene Ther. 2003 Jan;10(1):23-9
12489025
Hum Gene Ther. 2003 May 20;14(8):789-802
12804141